Intracellular Binding Site for a Positive Allosteric Modulator of the Dopamine D1 Receptor
- PMID: 30111649
- DOI: 10.1124/mol.118.112649
Intracellular Binding Site for a Positive Allosteric Modulator of the Dopamine D1 Receptor
Abstract
The binding site for DETQ [2-(2,6-dichlorophenyl)-1-((1S,3R)-3-(hydroxymethyl)-5-(2-hydroxypropan-2-yl)-1-methyl-3,4-dihydroisoquinolin-2(1H)-yl)ethan-1-one], a positive allosteric modulator (PAM) of the dopamine D1 receptor, was identified and compared with the binding site for CID 2886111 [N-(6-tert-butyl-3-carbamoyl-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)pyridine-4-carboxamide], a reference D1 PAM. From D1/D5 chimeras, the site responsible for potentiation by DETQ of the increase in cAMP in response to dopamine was narrowed down to the N-terminal intracellular quadrant of the receptor; arginine-130 in intracellular loop 2 (IC2) was then identified as a critical amino acid based on a human/rat species difference. Confirming the importance of IC2, a β2-adrenergic receptor construct in which the IC2 region was replaced with its D1 counterpart gained the ability to respond to DETQ. A homology model was built from the agonist-state β2-receptor structure, and DETQ was found to dock to a cleft created by IC2 and adjacent portions of transmembrane helices 3 and 4 (TM3 and TM4). When residues modeled as pointing into the cleft were mutated to alanine, large reductions in the potency of DETQ were found for Val119 and Trp123 (flanking the conserved DRY sequence in TM3), Arg130 (located in IC2), and Leu143 (TM4). The D1/D5 difference was found to reside in Ala139; changing this residue to methionine as in the D5 receptor reduced the potency of DETQ by approximately 1000-fold. None of these mutations affected the activity of CID 2886111, indicating that it binds to a different allosteric site. When combined, DETQ and CID 2886111 elicited a supra-additive response in the absence of dopamine, implying that both PAMs can bind to the D1 receptor simultaneously.
Copyright © 2018 The Author(s).
Similar articles
-
An Allosteric Potentiator of the Dopamine D1 Receptor Increases Locomotor Activity in Human D1 Knock-In Mice without Causing Stereotypy or Tachyphylaxis.J Pharmacol Exp Ther. 2017 Jan;360(1):117-128. doi: 10.1124/jpet.116.236372. Epub 2016 Nov 3. J Pharmacol Exp Ther. 2017. PMID: 27811173 Free PMC article.
-
Mutual Cooperativity of Three Allosteric Sites on the Dopamine D1 Receptor.Mol Pharmacol. 2023 Mar;103(3):176-187. doi: 10.1124/molpharm.122.000605. Epub 2022 Dec 12. Mol Pharmacol. 2023. PMID: 36804203
-
Identification of Positive Allosteric Modulators of the D1 Dopamine Receptor That Act at Diverse Binding Sites.Mol Pharmacol. 2018 Oct;94(4):1197-1209. doi: 10.1124/mol.118.113175. Epub 2018 Aug 1. Mol Pharmacol. 2018. PMID: 30068735 Free PMC article.
-
The First Negative Allosteric Modulator for Dopamine D2 and D3 Receptors, SB269652 May Lead to a New Generation of Antipsychotic Drugs.Mol Pharmacol. 2017 Jun;91(6):586-594. doi: 10.1124/mol.116.107607. Epub 2017 Mar 6. Mol Pharmacol. 2017. PMID: 28265019 Free PMC article. Review.
-
Exploring conceptual and theoretical frameworks for nurse practitioner education: a scoping review protocol.JBI Database System Rev Implement Rep. 2015 Oct;13(10):146-55. doi: 10.11124/jbisrir-2015-2150. JBI Database System Rev Implement Rep. 2015. PMID: 26571290
Cited by
-
Allosteric modulators restore orthosteric agonist binding to mutated CB1 receptors.J Pharm Pharmacol. 2020 Jan;72(1):84-91. doi: 10.1111/jphp.13193. Epub 2019 Nov 13. J Pharm Pharmacol. 2020. PMID: 31722122 Free PMC article.
-
Insights into the Interaction of LVV-Hemorphin-7 with Angiotensin II Type 1 Receptor.Int J Mol Sci. 2020 Dec 28;22(1):209. doi: 10.3390/ijms22010209. Int J Mol Sci. 2020. PMID: 33379211 Free PMC article.
-
A chemogenetic approach for dopamine imaging with tunable sensitivity.Nat Commun. 2024 Jul 2;15(1):5551. doi: 10.1038/s41467-024-49442-3. Nat Commun. 2024. PMID: 38956067 Free PMC article.
-
Modular Splicing Is Linked to Evolution in the Synapse-Specificity Molecule Kirrel3.eNeuro. 2023 Dec 5;10(12):ENEURO.0253-23.2023. doi: 10.1523/ENEURO.0253-23.2023. Print 2023 Dec. eNeuro. 2023. PMID: 37977826 Free PMC article.
-
Review on allosteric modulators of dopamine receptors so far.Health Sci Rep. 2024 Mar 18;7(3):e1984. doi: 10.1002/hsr2.1984. eCollection 2024 Mar. Health Sci Rep. 2024. PMID: 38505681 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous